Tampa firm launches peptide supply chain following new federal compounding rules

DataMEDS AI, a Nasdaq-listed healthcare company based in Tampa, announced Monday that its subsidiary Corexa Health will begin filling prescriptions for six experimental peptides this month. The move places the company in a rapidly shifting segment of the prescription drug market, acting on a supply agreement for substances that have never received approval from the Food and Drug Administration.

The decision follows a policy change issued by the U.S. Department of Health and Human Services on Oct. 30. That rule creates a limited pathway for licensed pharmacies to compound specific peptides while the FDA continues to review whether they belong on its list of permitted ingredients. The six compounds covered by the DataMEDS deal are BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. None of these have undergone FDA evaluation for safety or effectiveness.

Gerald Commissiong, the company’s interim co-CEO, stated that the firm aims to shift customers from online research-use markets into conventional prescription channels. “We believe that many gray market patients would prefer to purchase their peptides from a licensed pharmacy,” Commissiong said. This approach moves the substances into a system where physicians prescribe compounded preparations and pharmacists dispense them under federal and state requirements.

DataMEDS, formerly known as Wellgistics Health, will manage the logistics from a warehouse in Lakeland. The company plans to handle supplies from manufacturers and distribute the ingredients to qualifying compounding pharmacies. Its existing third-party logistics business supports a network of more than 6,500 independent pharmacies. The company has not disclosed how many of these locations will purchase the ingredients or offer the new prescriptions.

The FDA’s Pharmacy Compounding Advisory Committee reviewed the six substances during meetings on July 23 and 24. The committee examined proposed uses for wound healing, inflammatory conditions, obesity, insomnia, and neurological disorders. These applications remain unproven, and the new HHS enforcement policy does not constitute FDA approval. Participating pharmacies must meet strict requirements regarding ingredient sourcing, testing, patient-specific prescriptions, labeling, and the reporting of adverse events.

DataMEDS has not revealed the financial terms of the supply agreement, the identity of its supplier, or its expected revenue from the arrangement. The November rollout will operate through Corexa Pharmacy. This unit is part of a larger healthcare operation that includes pharmaceutical distribution, technology platforms, and a clinical diagnostics laboratory located in Pittsburgh.